EUVIMEDEUVIMED entdecken
Crossref

Evaluating RB1 and p53 as diagnostic markers in treatment‐related neuroendocrine prostate cancer through immunohistochemistry and genomic analysis of RB1 and TP53

Hideto Ueki iD, Naoe Jimbo, Tomoaki Terakawa iD, Takuto Hara iD, Taisuke Tobe, Junichiro Hirata, Naoto Wakita, Yasuyoshi Okamura, Kotaro Suzuki iD, Yukari Bando, Koji Chiba, Jun Teishima und 2 weitere

The Prostate · 2024

DOI: 10.1002/pros.24791 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2024. Verfasst von Hideto Ueki und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Immunohistochemistry, Biomarkers, Tumor, Retinoblastoma Binding Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The diagnosis of treatment‐related neuroendocrine prostate cancer (t‐NEPC) often involves a pathological assessment and immunohistochemistry (IHC) for neuroendocrine markers. Genomic alterations in RB1 and TP53 are frequently observed in NEPC and are believed to play a crucial role in the transformation of adenocarcinoma to NEPC. In this study, we examined the clinicopathologic, immunohistochemical, and genetic features of patients with t‐NEPC to better understand their prognosis and diagnostic utility.

Methods

This retrospective study reviewed the records of patients diagnosed with t‐NEPC at Kobe University Hospital between October 2018 and December 2022. Clinical data, including age, serum neuroendocrine marker levels, and treatment history, were collected. IHC was performed for conventional neuroendocrine markers (synaptophysin, chromogranin A, and CD56) and RB1 and p53 expression. Next‐generation sequencing (NGS) was conducted using FoundationOne® CDx to identify mutations in RB1 and TP53 .

Results

This study included 20 patients with t‐NEPC. The median time from ADT initiation to development was 42.8 months. IHC revealed RB1 loss in 75% of cases and p53 abnormalities in 75% of cases. NGS identified RB1 mutations in 55% and TP53 mutations in 75% of cases. The concordance between NGS and IHC results was high, with 70% (14/20) agreement for RB1/ RB1 and 80% (16/20) for p53/ TP53 . The immunostaining and genomic analysis of RB1/ RB1 and p53/ TP53 showed abnormal findings for the four negative cases for conventional neuroendocrine markers.

Conclusions

This study indicated high concordance between IHC and NGS findings for RB1/ RB1 and p53/ TP53 in t‐NEPC. We provide a comprehensive benchmark of NGS performance compared with IHC, and these findings may help increase the diagnostic sensitivity of t‐NEPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Suppressor Protein p53ImmunohistochemistryBiomarkers, TumorRetinoblastoma Binding ProteinsUbiquitin-Protein LigasesProstatic NeoplasmsHumansMaleRetrospective StudiesAgedMiddle AgedCarcinoma, NeuroendocrineAged, 80 and overMutation

Stichwörter der Autor:innen

NEPCRB1diagnostic markerimmunohistochemistryp53

Substanzen

Tumor Suppressor Protein p53RB1 protein, humanBiomarkers, TumorRetinoblastoma Binding ProteinsTP53 protein, humanUbiquitin-Protein Ligases

Autor:innen und Institutionen

  • Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe, Japan.

ORCID-Profile: Hideto Ueki, Tomoaki Terakawa, Takuto Hara, Kotaro Suzuki

Zitieren

APA

Ueki, H., Jimbo, N., Terakawa, T., Hara, T., Tobe, T., Hirata, J., Wakita, N., Okamura, Y., Suzuki, K., Bando, Y., Chiba, K., Teishima, J., Nakano, Y., & Miyake, H. (2024). Evaluating RB1 and p53 as diagnostic markers in treatment‐related neuroendocrine prostate cancer through immunohistochemistry and genomic analysis of RB1 and TP53. The Prostate. https://doi.org/10.1002/pros.24791

Vancouver

Ueki H, Jimbo N, Terakawa T, Hara T, Tobe T, Hirata J, et al. Evaluating RB1 and p53 as diagnostic markers in treatment‐related neuroendocrine prostate cancer through immunohistochemistry and genomic analysis of RB1 and TP53. The Prostate. 2024. doi:10.1002/pros.24791

BibTeX
@article{Ueki2024,
  author = {Ueki, Hideto and Jimbo, Naoe and Terakawa, Tomoaki and Hara, Takuto and Tobe, Taisuke and Hirata, Junichiro and Wakita, Naoto and Okamura, Yasuyoshi and Suzuki, Kotaro and Bando, Yukari and Chiba, Koji and Teishima, Jun and Nakano, Yuzo and Miyake, Hideaki},
  title = {Evaluating RB1 and p53 as diagnostic markers in treatment‐related neuroendocrine prostate cancer through immunohistochemistry and genomic analysis of RB1 and TP53},
  journal = {The Prostate},
  year = {2024},
  doi = {10.1002/pros.24791}
}
Kostenlos starten →